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Abstract: In addition to conventional clinicopathological parameters, molecular markers are also required
in order to predict the course of disease in patients with urothelial bladder cancer (BC). Little is known
about fibroblast growth factor receptor 3 (FGFR3) immunoreactivity and the clinical significance it may
possess with regard to BC. The present study aimed to investigate the immunoreactivity of FGFR3 in
primary urothelial bladder tumours, with regard to clinicopathological features and FGFR3 mutation
status. Tissue microarrays were used to immunohistochemically analyse FGFR3 expression in 255 pri-
mary, unselected patients with BC. FGFR3 mutations were detected using SNaPshot analysis. Positive
FGFR3 immunoreactivity was identified in 113/207 analysable cases (54.6%), and was significantly asso-
ciated with FGFR3 mutation (P<0.001), low tumour stage (P<0.001), low histological grade (P<0.001)
and a papillary growth pattern (P<0.001). Positive FGFR3 immunostaining (P=0.002) and FGFR3
mutation (P=0.002) were found to be significantly associated with increased disease-specific survival fol-
lowing univariate analysis, demonstrating a median follow-up period of 75 months. Using multivariate
analyses, FGFR3 immunoreactivity was found not to be independent of classical pathological param-
eters. Immunohistochemical expression of FGFR3 is an early occurrence during the carcinogenesis of
papillary non-invasive BC. The presence of FGFR3 immunoreactivity in non-invasive papillary urothelial
carcinomas may be utilised as an indicator of tumours possessing low-grade features and good prognosis.
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Abstract. In addition to conventional clinicopathological 
parameters, molecular markers are also required in order 
to predict the course of disease in patients with urothelial 
bladder cancer (BC). Little is known about fibroblast growth 
factor receptor 3 (FGFR3) immunoreactivity and the clinical 
significance it may possess with regard to BC. The present 
study aimed to investigate the immunoreactivity of FGFR3 
in primary urothelial bladder tumours, with regard to clini‑
copathological features and FGFR3 mutation status. Tissue 
microarrays were used to immunohistochemically analyse 
FGFR3 expression in 255 primary, unselected patients with 
BC. FGFR3 mutations were detected using SNaPshot analysis. 
Positive FGFR3 immunoreactivity was identified in 113/207 
analysable cases (54.6%), and was significantly associated 
with FGFR3 mutation (P<0.001), low tumour stage (P<0.001), 
low histological grade (P<0.001) and a papillary growth 
pattern (P<0.001). Positive FGFR3 immunostaining (P=0.002) 
and FGFR3 mutation (P=0.002) were found to be significantly 
associated with increased disease‑specific survival following 
univariate analysis, demonstrating a median follow‑up period 
of 75 months. Using multivariate analyses, FGFR3 immu‑
noreactivity was found not to be independent of classical 
pathological parameters. Immunohistochemical expression of 
FGFR3 is an early occurrence during the carcinogenesis of 
papillary non‑invasive BC. The presence of FGFR3 immuno‑
reactivity in non‑invasive papillary urothelial carcinomas may 
be utilised as an indicator of tumours possessing low‑grade 
features and good prognosis.
Introduction
The majority of patients (75‑80%) exhibiting bladder 
cancer (BC) typically present with papillary non‑invasive 
(stage pTa) or early invasive (stage pT1) urothelial tumours. The 
remaining 20‑25% of patients demonstrate more advanced, 
muscle‑invasive tumours (≥pT2) (1). A total of 70% of patients 
exhibiting stage pTa or pT1 BC will undergo recurrence, and 
up to 25% will develop muscle‑invasive tumours (2). There‑
fore, patients with BC must be carefully monitored for signs of 
disease recurrence or progression. However, to date, there are 
no established biomarkers in clinical practice that are able to 
predict the risk of tumour progression.
Based on genetic data, the 2004 World Health Organization 
(WHO) classification indicates that urinary bladder neoplasia 
may be subdivided into low‑ and high‑grade lesions (3). 
There are two genetic subtypes of BC tumour, which possess 
marked differences in their levels of genetic instability, and 
correspond to morphologically distinct entities (4). The first 
of these subtypes, the genetically stable category, includes 
low‑grade non‑invasive papillary tumours. The second genetic 
subtype, the genetically unstable category, encompasses 
high‑grade and invasive carcinomas, including pTaG3 and pTis, 
as well as ≥pT1, respectively (3). Burger et al (5) compared 
the WHO 1973 and 2004 tumour classification systems, and 
each system contributed significant information regarding 
the progression of BC. The inter‑observer variability of the 
WHO 2004 grading system, however, remains an unsolved 
problem for surgical pathology.
Fibroblast growth factor receptors (FGFRs) control crucial 
signalling pathways, which are responsible for numerous 
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cellular functions, including proliferation and migration (6). 
FGFRs have been revealed to possess an oncogenic role in 
numerous types of cancer (7). By contrast, FGFR signalling 
may also have a suppressive effect on tumours (6). It has been 
established that BC possesses a link with FGFR mutations, and 
~50% of BCs possess somatic mutations within the FGFR3 
coding sequence (8). Mutation of FGFR3 is a common feature 
of low‑grade, non‑invasive papillary urothelial BC, occurring 
in ~75% of cases (9‑12); while occurring at a markedly lower 
frequency in high‑grade invasive BC (13,14), and rarely with 
adjacent carcinoma in situ (9,14). Patients exhibiting primary 
BCs accompanied by an activating FGFR3 mutation had 
significantly improved disease‑specific survival (DSS) when 
compared with patients without FGFR3 mutations (11,15). 
FGFR3 and TP53 mutations were revealed to be mutually 
exclusive and may represent two distinct pathways for the 
development of BC (11,16,17). In these pathways, bladder 
cancer lesions with activating FGFR3 mutations represent 
a type of genetically stable, low‑grade, papillary tumour. In 
addition, amalgamation of the analysis of FGFR3 mutations 
and Ki‑67 immunohistochemistry, defined as molecular 
grading, was revealed to be superior to other parameters for 
predicting the progression and survival of patients exhibiting 
BC (11).
FGFR3 mutation status in BC, and the association of BC 
with the expression of FGFR3 protein, has previously been 
examined (18,19). The combination of WHO 2004 grading 
with FGFR3 mutation status facilitated improved risk stratifi‑
cation for patients exhibiting high‑grade, non‑muscle‑invasive 
urothelial BC (5). However, studies of FGFR3 immunore‑
activity and its clinical significance are uncommon (20,21). 
Immunohistochemical detection of the FGFR3 receptor may 
provide a simpler, cheaper and faster approach for histo‑
pathological practice, compared with the current method of 
determination of FGFR3 mutation status. Overall, FGFR3 
protein has significant potential for use as a diagnostic and 
prognostic marker, as well as a potential therapeutic target or 
screening tool (22).
In order to study the prognostic and diagnostic value of 
FGFR3 protein expression in urothelial BC, a large series 
of unselected primary urothelial BC tumours were analysed 
for FGFR3 immunoreactivity and FGFR3 mutations in asso‑
ciation with tumour stage, WHO 2004 grade, multifocality, 
presence of adjacent carcinoma in situ and patient outcome.
Patients and methods
Bladder cancer tissue microarray (TMA). As previously 
described (10), a TMA was generated using 255 consecu‑
tive, formalin‑fixed, paraffin‑embedded, primary urothelial 
BC tissue samples obtained from the Institute of Pathology, 
University of Regensburg (Regensburg, Germany). Clinical 
data were obtained from the Central Tumour Registry, 
Regensburg (Germany), and by telephone interviews when 
data could not be located. The Institutional Review Board 
of the University of Regensburg (Regensburg, Germany) 
approved the analysis of tissues from human subjects. 
Haematoxylin and eosin‑stained slides of all tumour samples 
were evaluated by a single surgical pathologist (Dr Arndt 
Hartman). Tumour stages and grades were assigned according 
to Union for International Cancer Control and WHO 2004 
criteria (www.uicc.org/). The growth pattern was determined 
for all tumours classified as invasive (≥pT1). Papillary growth 
was defined by the presence of a papillary tumour compo‑
nent (≥20%), possessing a histological grade identical to that 
of the invasive tumour. All other tumours were considered to 
possess a pattern of solid growth. Clinicopathological data 
are summarised in Table I. Retrospective clinical follow‑up 
data were available regarding the end‑points, defined 
as recurrence‑free survival (RFS) and disease‑specific 
survival (DSS), for all patients, and the median follow‑up 
period was 75 months (range, 0‑147 months). The median 
follow‑up period for censored patients was 81 months. Recur‑
rence was defined as the presence of cystoscopically visible 
tumours, and was further confirmed by histological verifica‑
tion. Data regarding progression‑free survival (PFS) were not 
available.
Immunohistochemistry. Immunohistochemical analysis 
used an avidin‑biotin peroxidase method with a diamino‑
benzidine chromatogen. Following antigen retrieval (using 
a microwave oven at 250 W for 30 min), immunohisto‑
chemistry was performed using an automated NEXES 
immunostainer (Ventana Medical Systems, Inc., Tucson, 
AZ, USA) according to the manufacturer's instructions. The 
following primary antibody was used: anti‑FGFR3 [rabbit 
monoclonal Immunoglobulin G, clone aa 359‑372 (E10234); 
Spring Bioscience, Fremont, CA, USA; dilution 1:50]. FGFR3 
immunoreactivity was scored as either negative or positive, 
irrespective of the staining intensity. Focal (partly posi‑
tive stained urothelial tissue on the TMA section) or weak 
FGFR3 (positive but with reduced intensity) immunoreactivity 
was also considered to be positive.
FGFR3 mutation analysis. FGFR3 mutation analysis was 
performed using the SNaPshot method as described previ‑
ously (12,22), using the ABI PRISM SNaPshot Multiplex Kit 
(Applied Biosystems, Foster City, CA, USA). Three regions 
of the FGFR3 gene, comprising all FGFR3 mutations identi‑
fied in BC (23), were simultaneously amplified in a multiplex 
polymerase chain reaction (PCR). Briefly, the multiplex PCR 
was performed in a volume of 15 µl, containing 1X PCR 
buffer, 1.5 mmol/l MgCl2, 0.5 U Taq polymerase (Promega 
Corporation, Madison, WI, USA), 0.17 mmol/l deoxynucleo‑
tide triphosphates (Roche Diagnostics, Basel, Switzerland), 
10 pmol of exon 7 and exon 15 primers, 7.5 pmol of exon 10 
primers (Invitrogen, Carlsbad, CA, USA), 5% glycerol 
(Fluka, Buchs SG, Switzerland), and 1‑250 ng of genomic 
DNA. Cycling conditions were as follows: 5 min at 95˚C, 
35 cycles at 95˚C for 45 sec, 60˚C for 45 sec, and 72˚C for 
45 sec, followed by 10 min at 72˚C. Following removal of 
excess primers and dNTPs, 8 SNaPshot primers for detection 
of 9 FGFR3 mutations were annealed to the PCR products 
and extended using a labelled dideoxynucleotide. These 
extended primers were analysed using an ABI PRISM 3100 
Genetic Analyzer automatic sequencer (Applied Biosystems, 
Foster City, CA, USA); the label attached to the incorporated 
nucleotide indicated the presence or absence of mutations. 
All mutations were verified using a second independent 
SNaPshot analysis.
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Statistical analysis. Statistical analyses were performed using 
the survival package in R version 3.0.3 (http://www.r‑project.
org) and SPSS version 22.0 (IBM SPSS, Armonk, NY, USA). 
P<0.05 was considered to indicate a statistically significant 
difference. Associations between the measured parameters 
were obtained by applying two‑sided χ2 and Fisher's exact 
tests. Non‑parametric Kaplan‑Meier estimators were used to 
analyse DSS. Point‑wise bands at a confidence level of 0.95 
were computed. Differences between survival estimates were 
evaluated using the Log‑Rank test. Cox regression analysis 
was performed for the variables with regard to DSS. For 
the analysis of RFS, patients were censored when cystec‑
tomy was performed or at the time of their last tumour‑free 
clinical follow‑up appointment. For DSS analysis, patients 
were censored at their final tumour‑free clinical follow‑up 
appointment or at their date of mortality unrelated to the 
tumour.
Results
Positive FGFR3 immunoreactivity and FGFR3 mutations are 
associated with positive histopathological characteristics. 
FGFR3 staining of any intensity was classified as positive, 
and was observed in 113/207 patients. Positive staining was 
mainly present in pTa/pT1 tumours (64%; 89/140). In addition, 
activating mutations in the FGFR3 gene were detected in 
98/208 (47%) analysable BC tumours, of which 59% (83/140) 
were pTa and pT1 tumours.
Table II exhibits the associations between FGFR3 immu‑
nohistochemistry and various clinicopathological parameters. 
A positive FGFR3 staining pattern was largely observed in 
tumours classified as low‑grade and stage pTa. In the low‑grade 
tumour group, 69% of tumours were FGFR3 positive (Table II) 
and 74% carried FGFR3 mutations (data not shown). Fig. 1A 
demonstrates a typical example of an FGFR3‑negative inva‑
sive high‑grade tumour, while Fig. 1B illustrates an example 
of an FGFR3 positive non‑invasive low‑grade tumour. In total, 
69% of pTa lesions were positive for FGFR3, as demonstrated 
by immunostaining. Fig. 2A and B depict the significant 
association between tumour stage and grade, and FGFR3 
immunoreactivity (both P<0.001). Papillary non‑invasive 
(pTa) and low‑grade tumours were predominantly positive for 
FGFR3, as demonstrated by immunohistochemical analysis. 
There was a significant association between positive FGFR3 
immunoreactivity and activating FGFR3 mutations (P<0.001; 
Fig. 2C).
Positive FGFR3 immunoreactivity was more frequent 
in tumours that did not posses adjacent carcinoma 
in situ (P=0.062). Considering only those tumours with solid 
growth patterns, which are known to be associated with a 
worse prognosis (24), positive FGFR3 immunoreactivity was 
present in a minority of cases (25%; P<0.001).
It was concluded that positive FGFR3 staining was 
associated with low tumour stage and grade, and with a papil‑
lary pattern of tumour growth (all P<0.001). In a previous 
study (12), FGFR3 mutation status was observed to be asso‑
ciated with identical clinicopathological parameters such as 
positive FGFR3 staining in the present study.
FGFR3 is a prognostic biomarker for patients with BC. 
The end‑points for the present study were RFS and DSS. 
Kaplan‑Meier analyses for DSS are exhibited in Fig. 3A 
and B, and reveal that BC patients with positive FGFR3 
staining had a significantly increased DSS compared with 
that of patients with negative FGFR3 staining (P=0.0018). In 
a subgroup analysis for high‑grade tumours, positive FGFR3 
Table I. Patient and tumour characteristics and results of 
molecular and immunohistochemical analyses.
Clinicopathological variable Cases, na (%)
Age at diagnosis, yearsb
  <70 141 (55.3)
  ≥70 114 (44.7)
Gender
  Female 64 (25.1)
  Male 191 (74.9)
Tumour stageb
  PUNLMP 22 (8.6)
  pTa 124 (48.6)
  pT1 48 (18.8)
  pT2 56 (22.0)
  pT3 2 (0.8)
  pT4 3 (1.2)
Histological gradec
  1 81 (31.8)
  2 69 (27.1)
  3 105 (41.2)
Histological graded
  Low 150 (58.8)
  High 105 (41.2)
Adjacent carcinoma in situ
  No 222 (87.1)
  Yes 33 (12.9)
Multiplicity
  Solitary 53 (20.8)
  Multifocal 202 (79.2)
Growth pattern
  Papillary 207 (81.5)
  Solid 47 (18.5)
FGFR3 gene
  Wild‑type 110 (52.9)
  Mutation 98 (47.9)
FGFR3 immunohistochemistry
  Negative 94 (45.4)
  Positive 113 (54.6)
aOnly the initial biopsy of each patient is included. Total cases ana‑
lysed, 255. bMedian, 68 years and range, 34‑95 years. cStaging and 
grading according to the WHO 1973 classification system. dStaging 
and grading according to the WHO 2004 classification system. 
FGFR3, fibroblast growth factor receptor 3; PUNLMP, papillary 
urothelial neoplasia of low malignant potential. Certain cases were 
not analysed successfully due to insufficient material.
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staining demonstrated a trend for improved prognosis 
(Fig. 3B), however this trend was not statistically signifi‑
cant (P=0.0991).
Fig. 3C summarises the results of the univariate survival 
analysis for DSS and indicates that positive FGFR3 staining 
is associated with longer DSS (hazard ratio, 0.35; 95% 
Figure 1. Immunohistochemical staining with FGFR3 antibody. (A) Representative image of negative FGFR3 staining in a high‑grade invasive urothelial 
tumour. (B) Representative imageof positive FGFR3 immunoreactivity in a low‑grade non‑invasive urothelial bladder cancer specimen. FGFR3, fibroblast 
growth factor receptor 3.
Table II. Comparison of FGFR3 immunoreactivity with clinicopathological and IHC parameters (n=207).
 FGFR3 IHC staining pattern
 ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑
Clinicopathological variable Negative, n Positive, n P‑value
Tumour stagea   <0.001c
  PUNLMP   6     8
  pTa 31   68
  pT1 20   21
  pT2 34   14
  pT3   0     2
  pT4   3     0
Histological gradea   <0.001c
  1 23   35
  2 13   47
  3 58   31
Histological gradeb   <0.001c
  Low 36   82
  High 58   31
Adjacent carcinoma in situb   0.062
  No  77 103
  Yes 17   10
Multiplicityb   1.000
  Solitary 20   25
  Multifocal 74   88
Growth patternb,d   <0.001c
  Papillary 63 103
  Solid 30   10
aχ2‑test (two‑sided); bFisher's exact test (two‑sided). cA statistically significant difference. d One sample could not be evaluated for papillary or 
solid tumor growth. PUNLMP, papilllary urothelial neoplasia of low malignant potential; FGFR3, fibroblast growth factor receptor 3; IHC, 
immunohistochemistry.
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confidence interval, 0.18‑0.70; P=0.0030). Multivariate Cox 
regression analysis revealed that FGFR3 immunoreactivity 
was not observed to be a significant parameter associated with 
DSS (data not shown). None of the investigated parameters 
demonstrated a correlation with RFS (data not shown).
Discussion
The present study aimed to investigate FGFR3 immunoreac‑
tivity as a potential prognostic biomarker and diagnostic tool 
in surgical pathology, for patients with BC. The results of the 
present study revealed that FGFR3 immunoreactivity of any 
intensity was markedly associated with a low tumour grade 
and stage, and longer DSS. 
In the present study, increased protein expression was 
identified in 69% of pTa and 51% of pT1 tumours. This 
finding corresponds with the results of previous studies, 
which have previously investigated FGFR3 protein expression 
using immunohistochemistry, which have reported similar 
percentages of increased FGFR3 protein expression to those 
observed in the present study (18,19,23). Accordingly, the 
aforementioned studies identified a significant association 
between FGFR3 expression and tumour stage and grade. 
By contrast, Matsumoto et al (25) identified no association 
between FGFR3 expression levels and pathological param‑
eters, including grade and stage, potentially due to the low 
number of cases evaluated leading to a low statistical power 
(n=126).
Furthermore, the present study demonstrated a correla‑
tion between FGFR3 expression and FGFR3 mutation. In the 
present study, 74% of tumours with positive FGFR3 expres‑
sion demonstrated an FGFR3 mutation. This association has 
additionally been verified using semi‑quantitative reverse 
transcription‑PCR, where FGFR3 messenger RNA expression 
was clearly associated with FGFR3 mutation status (26). Simi‑
larly to the results of the present study, Tomlinson et al (18) 
demonstrated a significant association between FGFR3 
expression levels and FGFR3 mutation, as well as tumour 
grade and stage, respectively.
Previously, FGFR3 mutation status has been demonstrated 
to be a marker for the prognosis of patients with BC (11,27,28). 
In the present study, the correlation between FGFR3 mutations 
and tumours of low stage and grade was confirmed (9,11). 
Previous studies have investigated the use of FGFR3 expres‑
sion as a predictor of prognosis in BC. While a number of 
authors were able to demonstrate a shorter RFS associated 
Figure 2. Comparison of FGFR3 staining intensity with (A) grade, (B) stage and (C) FGFR3 mutation of tumours. Frequency represents the percentage of 
tumours in a particular stage or grade. Dark blue bars represent FGFR3 negative staining and light blue bars represent FGFR3 positive staining. FGFR3, 
fibroblast growth factor receptor 3; IHC, immunohistochemistry; PUNLMP, papilllary urothelial neoplasia of low malignant potential.
  A   B
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with FGFR3 expression (20,29), Gudjonsson et al (21) did 
not identify any difference in time to recurrence. In general, 
the role of molecular markers for predicting BC recurrence 
appears to be limited, as reviewed by van Rhijn (30). Even the 
FGFR3 mutation, which facilitates selective identification of 
non‑muscle‑invasive BC with good prognosis, did not predict 
recurrence in two studies investigating >200 patients, alone or 
in combination with other molecular markers (5,11). Therefore, 
it was not noteworthy that the present study was unable to 
predict recurrence using FGFR3 mutation or expression.
To best of our knowledge, the present study is the first 
report of an association between FGFR3 protein expression 
and DSS. The present study demonstrated that in addition 
to FGFR3 mutation, FGFR3 protein expression was able to 
predict longer DSS in patients with BC. However, FGFR3 
protein expression did not remain an independent predictor of 
worse DSS following multivariate analysis.
FGFR3 mutation has been proven to be capable 
of predicting prognosis in several previous studies. 
Tomlinson et al (18), described the association between 
Figure 3. Kaplan‑Meier survival plots with point‑wise confidence bands (confidence level, 0.95) for disease‑specific survival based on FGFR3 staining in 
(A) all (n=207) immunohistochemically analysable patients and in (B) a subgroup analysis (n=89) considering only high‑grade tumours. Log‑Rank tests were 
performed to test for equality in the survival expectation of each group. N‑values represent the number of patients in each group. (C) A forest plot for the 
univariate Cox regression analysis of factors potentially affecting disease‑specific survival of patients with urothelial bladder cancer. The dashed vertical line 
indicates the no effect point (a hazard ratio of 1.0). Horizontal lines represent 95% confidence intervals. The midpoint and the area of the box illustrate the mean 
effect estimate and the weight of each subgroup. FGFR3, fibroblast growth factor 3; IHC, immunohistochemistry; PUNLMP, papilllary urothelial neoplasia of 
low malignant potential; WHO, world health organisation; uni/multi, solitary/multifocal; neg/pos, negative/positive.
  A   B
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FGFR3 mutation and protein expression levels, and identi‑
fied a marked association between FGFR3 protein expression 
and tumour grade and stage. However, data on progression 
and DSS were not presented. Bodoor et al (31) studied 
FGFR3 protein expression and disease course and identi‑
fied no association between FGFR3 expression and overall 
survival, although data on DSS was not available. However, 
two recent studies reported no association between FGFR3 
protein expression and prognosis. Guancial et al (32) and 
Turo et al (33) investigated FGFR3 protein expression in 
muscle‑invasive BC and identified no association with overall 
survival. Guancial et al (32) investigated FGFR3 protein 
expression in 231 primary invasive BCs, while Turo et al (33) 
studied FGFR3 protein expression in 150 invasive BCs. 
Guancial et al (32) found FGFR3 mutations in just 2% of all 
tumours, whereas Turo et al (33) did not investigate FGFR3 
mutation status. 
In the present study it was revealed that FGFR3 protein 
expression was increased in tumours of lower stage and grade. 
Consequently, FGFR3 protein expression was associated with 
improved outcomes, as grading and staging are significant, 
well‑known pathological predictors for disease progression in BC.
A significant limitation of the present study was that a 
major end‑point for BC, PFS, was not able to be assessed in 
this cohort. FGFR3 protein expression was not an indepen‑
dent marker, but was markedly influenced by the pathological 
parameters, stage and grade for the prediction of disease 
course. However, FGFR3 protein expression has the potential 
to serve as an additional molecular marker, alongside tumour 
grading and staging, in the prediction of prognosis.
FGFR3 mutation analysis using the SNaPshot method 
has not been implemented in routine practice, due to the high 
associated costs and complexity. By contrast, FGFR3 immuno‑
histochemistry appears to be more convenient and feasible for 
use on a routine basis. Analysis of FGFR3 protein expression 
may provide a tool for use in the assessment of the prognosis 
of patients exhibiting BC. The present study proposes to use 
FGFR3 immunoreactivity as an additional diagnostic measure 
for grading in difficult cases, to better differentiate between 
low‑ and high‑grade urothelial lesions.
The prognosis of non‑muscle‑invasive BC relies on 
clinicopathological variables to predict outcomes. The present 
study revealed that the FGFR3 receptor is a significant, but 
not independent, marker for DSS of BC patients. The present 
study concluded that FGFR3 protein expression and mutant 
FGFR3 may provide prognostic information for non‑invasive 
BC, and may aid pathologists with appropriate grading in 
difficult cases. In addition, loss of FGFR3 expression may 
identify a subgroup of high‑grade tumours with worse prog‑
noses. Further prospective studies evaluating all end‑points 
are required to confirm these data.
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